香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 董事會召開日期 雋泰控股有限公司（「本公司」）董事會（「董事會」）謹此公佈，本公司訂於二零 二五年八月二十九日（星期五）舉行董事會會議，以（其中包括）批准本公司及其 附屬公司截至二零二五年六月三十日止六個月之未經審核綜合中期業績公告，及 考慮宣派中期股息（如有）。 承董事會命 雋泰控股有限公司 主席 賈明暉 香港，二零二五年八月十一日 於本公告日期，執行董事為賈明暉先生（主席）及張亨鑫先生；而獨立非執行董事 為葉夢美女士、歐陽銘賢先生及郭鎮輝先生。 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: AMCO United Holding Limited 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 HKD | | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 HKD | | | 400,000,000 | 本月底法 ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Company Overview - JunTai Holdings Limited is a company registered in Bermuda, primarily engaged in the manufacturing and sales of medical equipment, plastic molds, and data media products [2] Financial Performance - As of December 31, 2024, JunTai Holdings reported total revenue of 34.9969 million yuan, a year-on-year increase of 10.07% [1] - The company recorded a net profit attributable to shareholders of -1.1418 million yuan, reflecting a year-on-year growth of 55.21% [1] - The gross profit margin stood at 36.89%, while the debt-to-asset ratio was 62.26% [1] Stock Performance - On July 16, the Hang Seng Index fell by 0.29%, closing at 24,517.76 points [1] - JunTai Holdings' stock closed at 0.335 HKD per share, marking an increase of 11.67% with a trading volume of 901,900 shares and a turnover of 302,600 HKD [1] - Over the past month, JunTai Holdings has seen a cumulative increase of 316.67%, and a year-to-date increase of 150%, outperforming the Hang Seng Index by 22.58% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.39 times, with a median of 1.17 times [1] - JunTai Holdings has a P/E ratio of -235.41 times, ranking 56th in the industry [1] - Comparatively, other companies in the sector have P/E ratios such as Star Medical Holdings at 0.26 times, Kingjoy Health at 0.38 times, and others ranging from 1.96 to 5.35 times [1]

Group 1 - The core viewpoint of the article highlights the significant stock performance of JunTai Holdings, with a recent increase of 465.22% over the past month and 116.67% year-to-date, outperforming the Hang Seng Index by 19.78% [1] - As of December 31, 2024, JunTai Holdings reported total revenue of 34.9969 million yuan, a year-on-year increase of 10.07%, and a net profit attributable to shareholders of -1.1418 million yuan, reflecting a year-on-year growth of 55.21% [1] - The company's gross profit margin stands at 36.89%, with a debt-to-asset ratio of 62.26% [1] Group 2 - JunTai Holdings operates primarily in the manufacturing and sales of medical equipment products, plastic molds, and data media products, having expanded its medical equipment business through the acquisition of the Titron Group in October 2011 [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.68 times, with a median of 1.17 times, while JunTai Holdings has a P/E ratio of -204.03 times, ranking 56th in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as Giant Medical Holdings at 0.28 times, Jingjiu Health at 0.38 times, Yihui Group at 1.96 times, Global Medical at 5.24 times, and Ruici Medical at 5.4 times [1]

Key Points - As of June 30, 100 stocks reached their 52-week highs, with JunTai Holdings (00630), Chow Tai Fook (06168), and HOME CONTROL (01747) leading the high rate at 93.94%, 28.22%, and 27.65% respectively [1] - The closing prices for the top three stocks were 0.270, 48.450, and 2.130, with their highest prices being 0.320, 51.800, and 2.350 respectively [1] - Other notable stocks that reached new highs include China Star Group (00326) at 24.46%, New Fire Technology Holdings (01611) at 21.32%, and Fuyou Holdings (08269) at 20.53% [1] 52-Week High Rankings - JunTai Holdings (00630) achieved a high rate of 93.94% with a closing price of 0.270 and a peak price of 0.320 [1] - Chow Tai Fook (06168) reached a high rate of 28.22%, closing at 48.450 with a peak of 51.800 [1] - HOME CONTROL (01747) had a high rate of 27.65%, closing at 2.130 and peaking at 2.350 [1] Additional Stocks - China Star Group (00326) reached a high rate of 24.46% with a closing price of 2.290 [1] - New Fire Technology Holdings (01611) had a high rate of 21.32% with a closing price of 3.100 [1] - Fuyou Holdings (08269) achieved a high rate of 20.53% with a closing price of 0.180 [1]

Group 1 - The Hang Seng Index closed down 1.36% at 24035.38 points on June 12, with JunTai Holdings (00630.HK) closing at HKD 0.064 per share, up 39.13% with a trading volume of 250,000 shares and a turnover of HKD 14,200 [1] - Over the past month, JunTai Holdings has shown a cumulative increase of 0%, while it has a year-to-date decline of 61.67%, underperforming the Hang Seng Index by 21.47% [1] - Financial data as of December 31, 2024, indicates that JunTai Holdings achieved total revenue of HKD 34.9969 million, a year-on-year increase of 10.07%, and a net profit attributable to shareholders of -HKD 1.1418 million, a year-on-year increase of 55.21%, with a gross margin of 36.89% and a debt-to-asset ratio of 62.26% [1] Group 2 - Currently, there are no institutional investment ratings for JunTai Holdings [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry (TTM) is -21.87 times, with a median of 0.4 times; JunTai Holdings has a P/E ratio of -36.1 times, ranking 65th in the industry [2] - Other companies in the industry include Jingjiu Kangliao (00648.HK) with a P/E ratio of 0.38 times, Juxing Medical Holdings (02393.HK) at 0.42 times, Yongsheng Medical (01612.HK) at 3.87 times, Global Medical (02666.HK) at 4.7 times, and Ruici Medical (01526.HK) at 5.45 times [2]

Company Overview - JunTai Holdings Limited is a company registered in Bermuda and listed on the Hong Kong Stock Exchange since 1996, primarily engaged in the manufacturing and sales of medical equipment, plastic molds, and data media products [2] Financial Performance - As of December 31, 2024, JunTai Holdings reported total revenue of 34.9969 million yuan, representing a year-on-year growth of 10.07% [1] - The company recorded a net profit attributable to shareholders of -1.1418 million yuan, showing a year-on-year increase of 55.21% [1] - The gross profit margin stood at 36.89%, while the debt-to-asset ratio was 62.26% [1] Stock Performance - On May 23, the Hang Seng Index rose by 0.24%, closing at 23,601.26 points, while JunTai Holdings' stock price increased by 42.86% to 0.06 HKD per share, with a trading volume of 65,300 shares and a turnover of 3,840 HKD [1] - Over the past month, JunTai Holdings has experienced a cumulative decline of 16%, and a year-to-date decline of 65%, underperforming the Hang Seng Index's increase of 17.37% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -19.66 times, with a median of 0.31 times [1] - JunTai Holdings has a P/E ratio of -32.96 times, ranking 65th in the industry [1] - Other companies in the industry include Giant Medical Holdings (0.25 times), Jingjiu Health (0.38 times), Yongsheng Medical (4.01 times), Global Medical (4.58 times), and Ruici Medical (5.4 times) [1]

Financial Performance - The total revenue of AMCO United Holding Limited increased by HK$3.5 million or 10.2%, from HK$34.3 million in 2023 to HK$37.8 million in 2024[17]. - The loss for the year decreased from HK$2.75 million in 2023 to HK$1.23 million in 2024, representing a reduction of approximately 55.4%[6]. - The equity attributable to owners of the Company decreased slightly from HK$61.36 million in 2023 to HK$60.13 million in 2024[6]. - The current ratio improved from 2.2 in 2023 to 2.3 in 2024, indicating better short-term financial health[6]. - The return on total assets improved from (1.6%) in 2023 to (0.8%) in 2024, reflecting a reduction in losses relative to total assets[6]. - Gross profit decreased by HK$0.9 million or 6.1% to HK$13.9 million, with a gross profit margin decline of 6.2 percentage points to 36.9%[27]. - The overall loss attributable to owners of the Company decreased by HK$1.6 million or 57.1% to HK$1.2 million compared to a loss of HK$2.8 million in 2023[30]. Business Segments - The Group's Money Lending Business generated stable income in 2024, while the Securities Investment segment recorded a loss[19]. - Medical Products revenue rose by HK$3.7 million or 16.9% to HK$25.6 million, accounting for 67.6% of the Group's total revenue[35]. - The segment profit for Medical Products increased to HK$4.2 million in 2024 from HK$3.3 million in 2023, aided by the reversal of impairment loss under ECL[39]. - The segment loss for Plastic Products in 2024 was approximately HK$1,546,000, an increase of HK$717,000 compared to a loss of approximately HK$829,000 in 2023[109]. - The segment profit from Money Lending amounted to HK$7.3 million, down from HK$14.7 million in 2023[114]. Operational Strategies - The Group plans to maintain liquidity by effectively managing working capital and controlling costs in response to market uncertainties[22]. - The Group aims to optimize its business portfolio and explore new growth potentials to maximize shareholder value[23]. - The Group is focused on dynamic performance evaluation and asset reallocation to adapt to market changes and enhance operational efficiency[24]. - The Group employs a just-in-time production strategy to enhance competitiveness, allowing for quick adjustments in production volumes and product mix according to market demand[85]. - The procurement department monitors raw material consumption and adjusts procurement based on sales orders and forecasts to minimize storage costs and obsolete stock risks[85]. Customer Engagement and Market Development - The Group is actively exploring potential business opportunities to expand its customer base in the Medical Devices Business[18]. - The customer base mainly consists of users and distributors in the PRC, including retailers and trading companies[51][54]. - The Group is actively seeking new opportunities to broaden its customer base through various channels, including referrals and business events[52][53]. Investment and Financial Management - The Group recorded loan interest income of HK$11.2 million from its Money Lending, representing a decrease of HK$0.6 million or 5.1% compared to HK$11.8 million for the previous year, accounting for 29.7% of the Group's total revenue[114]. - The Group experienced net impairment losses of approximately HK$3.0 million for expected credit losses and write-offs on loan and interest receivables for the year ended December 31, 2024[120]. - The Group intends to diversify its investment portfolio to reduce concentration and investment risks in light of recent market volatility[137]. - The Group has a policy for assessing credit risk based on close monitoring, including aging analysis and past collection history[134]. Governance and Management - The Group's management team includes experienced professionals with backgrounds in finance, human resources, and e-commerce[163][164][173]. - The Board consists of two Executive Directors and three Independent Non-executive Directors, ensuring a balanced composition[178]. - The Company complied with all provisions of the Corporate Governance Code throughout the year ended December 31, 2024, with certain disclosed deviations[175]. - Each Executive Director is suitably qualified and possesses sufficient experience to effectively carry out their duties[191]. Quality Control and Production - The Group emphasizes consistent product quality through a stringent quality control system to meet relevant medical device standards[45][48]. - Quality control measures are implemented throughout the production process to ensure that finished products meet safety standards and customer specifications[78]. - The Group's production process includes manual testing and assembly steps to ensure the quality of medical devices before packaging[90]. Future Outlook - The Board anticipates stable market demand for medical products, particularly lancet piping parts and devices, due to the increasing prevalence of diabetes, projected to affect 783 million adults by 2045[103]. - The demand for medical products is expected to grow due to increased public health awareness post-COVID-19, with stable revenue anticipated from pandemic-related products[106].

Group 1 - The stock of Puli Pharmaceutical (普利制药) entered the delisting preparation period, with its stock price plummeting by over 70% at one point, reaching a maximum drop of 77.51% during trading [4][5][7] - The company previously announced that its 2021 and 2022 annual reports contained false records, with a total false profit amounting to 669 million yuan, accounting for 73.83% of the total disclosed profits for those two years [7] - The delisting preparation period for the company's stock and convertible bonds started on April 28, 2025, lasting for fifteen trading days, with the expected last trading date on May 21, 2025 [7][8] Group 2 - During the delisting preparation period, the company's stock will trade on the Shenzhen Stock Exchange's risk warning board, with no price limits on the first day, followed by a daily limit of 20% thereafter [8] - The company has warned investors that its stock is classified as a special security under the Shenzhen Stock Connect, meaning investors can only sell and not buy, which may affect future trading [8] Group 3 - In the A-share market, other sectors such as steel, internet, banking, and electricity showed gains, while real estate, tourism, and home goods sectors experienced declines [2] - Goldwind Technology (金风科技) reported a significant increase in its first-quarter revenue for 2025, achieving 9.472 billion yuan, a year-on-year growth of 35.72%, and a net profit of 568 million yuan, up 70.84% [3]